Search

Your search keyword '"Komajda, Michel"' showing total 1,432 results
Start Over Author "Komajda, Michel"
1,432 results on '"Komajda, Michel"'

5. Introduction hospitalière des traitements de l'insuffisance cardiaque à fraction d'éjection altérée < 50 % : mise au point et proposition d'algorithme

Author

Charbonnel, Clément, Jagu, Annabelle, Vannier, Claire, De Cordoue, Maylis, Aroulanda, Marie-José, Lozinguez, Olivier, Komajda, Michel, Garcon, Philippe, Antakly-Hanon, Yara, Moeuf, Yoann, Lesage, Jean-Baptiste, Mantes, Lucie, Midey, Charlotte, Izabel, Mathilde, Boukefoussa, Wahiba, Manne, Julien, Standish, Brigitte, Duc, Philippe, Iliou, Marie-Christine, and Cador, Romain

Published
2023
Full Text
View/download PDF

6. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF

Author

Pitt, Bertram, Bhatt, Deepak L., Szarek, Michael, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Voors, Adriaan A., Metra, Marco, Lund, Lars H., Komajda, Michel, Testani, Jeffrey M., Wilcox, Christopher S., Ponikowski, Piotr, Lopes, Renato D., Ezekowitz, Justin A., Sun, Franklin, Davies, Michael J., Verma, Subodh, Kosiborod, Mikhail N., and Steg, Ph. Gabriel

Published
2023
Full Text
View/download PDF

10. Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation

Author

Bowman, Louise, Weidinger, Franz, Albert, Michelle A., Fry, Edward T.A., Pinto, Fausto J., Achenbach, Stephan, Bowman, Louise, Casadei, Barbara, Collins, Rory, Devereaux, Philip J., Douglas, Pamela S., Frobert, Ole, Goto, Shinya, Grines, Cindy, Harrington, Robert A., Haynes, Richard, Hochman, Judith S., James, Stefan, Kirchhof, Paulus, Komajda, Michel, Lam, Carolyn S.P., Landray, Martin, Maggioni, Aldo, McMurray, John, Medhurst, Nick, Neal, Bruce, Rydén, Lars, Thiele, Holger, Van Gelder, Isabelle, Wallentin, Lars, Yusuf, Salim, and Zannad, Faiez

Published
2023
Full Text
View/download PDF

18. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Author

Packer, Milton, Butler, Javed, Zannad, Faiez, Filippatos, Gerasimos, Ferreira, Joao Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Schnaidt, Sven, Zeller, Cordula, Schnee, Janet M., and Anker, Stefan D.

Published
2021
Full Text
View/download PDF

20. Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry

Author

Abdin, Amr, primary, Anker, Stefan D., additional, Cowie, Martin R., additional, Filippatos, Gerasimos S., additional, Ponikowski, Piotr, additional, Tavazzi, Luigi, additional, Schöpe, Jakob, additional, Wagenpfeil, Stefan, additional, Komajda, Michel, additional, and Böhm, Michael, additional

Published
2023
Full Text
View/download PDF

21. Ivabradine

Author

Komajda, Michel, Barrett, James E., Editor-in-chief, Flockerzi, Veit, Series editor, Frohman, Michael A., Series editor, Geppetti, Pierangelo, Series editor, Hofmann, Franz B., Series editor, Michel, Martin C., Series editor, Page, Clive P, Series editor, Rosenthal, Walter, Series editor, Wang, KeWei, Series editor, Bauersachs, Johann, editor, Butler, Javed, editor, and Sandner, Peter, editor

Published
2017
Full Text
View/download PDF

25. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Author

Packer, Milton, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Brueckmann, Martina, Jamal, Waheed, Zeller, Cordula, Schnaidt, Sven, and Zannad, Faiez

Published
2021
Full Text
View/download PDF

26. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

Author

Metra, Marco, Eichhorn, Eric, Abraham, William T, Linseman, Jennifer, Böhm, Michael, Corbalan, Ramon, DeMets, David, De Marco, Teresa, Elkayam, Uri, Gerber, Michael, Komajda, Michel, Liu, Peter, Mareev, Vyacheslev, Perrone, Sergio V, Poole-Wilson, Philip, Roecker, Ellen, Stewart, Jennifer, Swedberg, Karl, Tendera, Michal, Wiens, Brian, and Bristow, Michael R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Clinical Trials and Supportive Activities, Rehabilitation, Cardiovascular, Heart Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Administration, Oral, Adult, Aged, Blood Pressure, Cardiotonic Agents, Chronic Disease, Double-Blind Method, Enoximone, Exercise, Exercise Tolerance, Heart Failure, Heart Rate, Hospitalization, Humans, Kaplan-Meier Estimate, Middle Aged, Young Adult, Advanced heart failure, Inotropic agents, ESSENTIAL Investigators, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

AimsUse of inotropic agents in patients with heart failure (HF) has been limited by adverse effects on outcomes. However, administration of positive inotropes at lower doses and concomitant treatment with beta-blockers might increase benefit-risk ratio. We investigated the effects of low doses of the positive inotrope enoximone on symptoms, exercise capacity, and major clinical outcomes in patients with advanced HF who were also treated with beta-blockers and other guideline-recommended background therapy.Methods and resultsThe Studies of Oral Enoximone Therapy in Advanced HF (ESSENTIAL) programme consisted of two identical, randomized, double-blind, placebo-controlled trials that differed only by geographic location (North and South America: ESSENTIAL-I; Europe: ESSENTIAL-II). Patients with New York Heart Association class III-IV HF symptoms, left ventricular ejection fraction < or = 30%, and one hospitalization or two ambulatory visits for worsening HF in the previous year were eligible for participation in the trials. The trials had three co-primary endpoints: (i) the composite of time to all-cause mortality or cardiovascular hospitalization, analysed in the two ESSENTIAL trials combined; (ii) the 6 month change from baseline in the 6 min walk test distance (6MWTD); and (iii) the Patient Global Assessment (PGA) at 6 months, both analysed in each trial separately. ESSENTIAL-I and -II randomized 1854 subjects at 211 sites in 16 countries. In the combined trials, all-cause mortality and the composite, first co-primary endpoint did not differ between the two treatment groups [hazard ratio (HR) 0.97; 95% confidence interval (CI) 0.80-1.17; and HR 0.98; 95% CI 0.86-1.12, respectively, for enoximone vs. placebo]. The two other co-primary endpoints were analysed separately in the two ESSENTIAL trials, as prospectively designed in the protocol. The 6MWTD increased with enoximone, compared with placebo, in ESSENTIAL-I (P = 0.025, not reaching, however, the pre-specified criterion for statistical significance of P < 0.020), but not in ESSENTIAL-II. No difference in PGA was observed in either trial.ConclusionAlthough low-dose enoximone appears to be safe in patients with advanced HF, major clinical outcomes are not improved.

Published
2009

27. Patient journey in decompensated heart failure: An analysis in departments of cardiology and geriatrics in the Greater Paris University Hospitals

Author

Laveau, Florent, Hammoudi, Nadjib, Berthelot, Emmanuelle, Belmin, Joël, Assayag, Patrick, Cohen, Ariel, Damy, Thibaud, Duboc, Denis, Dubourg, Olivier, Hagege, Albert, Hanon, Olivier, Isnard, Richard, Jondeau, Guillaume, Labouree, Florian, Logeart, Damien, Mansencal, Nicolas, Meune, Christophe, Pautas, Eric, Wolmark, Yves, and Komajda, Michel

Published
2017
Full Text
View/download PDF

32. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction

Author

Dewan, Pooja, Rørth, Rasmus, Raparelli, Valeria, Campbell, Ross T., Shen, Li, Jhund, Pardeep S., Petrie, Mark C., Anand, Inder S., Carson, Peter E., Desai, Akshay S., Granger, Christopher B., Køber, Lars, Komajda, Michel, McKelvie, Robert S., O’Meara, Eileen, Pfeffer, Marc A., Pitt, Bertram, Solomon, Scott D., Swedberg, Karl, Zile, Michael R., and McMurray, John J.V.

Published
2019
Full Text
View/download PDF

34. Personalized care of patients with heart failure: are we ready for a REWOLUTION ? Insights from two international surveys on healthcare professionals' needs and patients' perceptions

Author

Jankowska, Ewa A., primary, Liu, Peter P., additional, Cowie, Martin R., additional, Groenhart, Max, additional, Cobey, Kelly D., additional, Howlett, Jonathan, additional, Komajda, Michel, additional, Lund, Lars H., additional, Magaña Serrano, Jose Antonio, additional, Mourilhe‐Rocha, Ricardo, additional, Rosano, Giuseppe M.C., additional, Saldarriaga, Clara, additional, Schwartzmann, Pedro V., additional, Zannad, Faiez, additional, Zhang, Jian, additional, Zhang, Yuhui, additional, and Coats, Andrew J.S., additional

Published
2023
Full Text
View/download PDF

35. Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial)

Author

Metra, Marco, Mentz, Robert J., Hernandez, Adrian F., Heizer, Gretchen M., Armstrong, Paul W., Clausell, Nadine, Corbalan, Ramon, Costanzo, Maria Rosa, Dickstein, Kenneth, Dunlap, Mark E., Ezekowitz, Justin A., Howlett, Jonathan G., Komajda, Michel, Krum, Henry, Lombardi, Carlo, Fonarow, Gregg C., McMurray, John J.V., Nieminen, Markku S., Swedberg, Karl, Voors, Adriaan A., Starling, Randall C., Teerlink, John R., and O'Connor, Christopher M.

Published
2016
Full Text
View/download PDF

36. Maladies rares, le modèle français

Author

Cordier, Jean-François, Fischer, Alain, Guillevin, Loïc, Fiessinger, Jean-Noël, Lyonnet, Stanislas, Barois, Annie, Bégué, Pierre, Bouvenot, Gilles, Brice, Alexis, Buffet, Catherine, Cartier-Lacave, Nathalie, Delpech, Marc, Éléfant, Élisabeth, Giudicelli, Claude-Pierre, Godeau, Pierre, Grosbois, Bernard, Hauw, Jean-Jacques, Juillet, Yves, Komajda, Michel, Lacombe, Didier, Léger, Jean-Marc, Lhermitte, Michel, Peix, Jean-Louis, Poupon, Raoul, Queneau, Patrice, Ronco, Pierre, Rouëssé, Jacques, and Vert, Paul

Published
2016
Full Text
View/download PDF

39. Efficacy of ivabradine in heart failure patients with a high‐risk profile (analysis from the SHIFT trial).

Author

Abdin, Amr, Komajda, Michel, Borer, Jeffrey S., Ford, Ian, Tavazzi, Luigi, Batailler, Cécile, Swedberg, Karl, Rosano, Giuseppe M.C., Mahfoud, Felix, and Böhm, Michael

Subjects
HEART failure patients, IVABRADINE, SYSTOLIC blood pressure, VENTRICULAR ejection fraction, HEART beat
Abstract

Aims: Early start and patient profile‐oriented heart failure (HF) management has been recommended. In this post hoc analysis from the SHIFT trial, we analysed the treatment effects of ivabradine in HF patients with systolic blood pressure (SBP) < 110 mmHg, resting heart rate (RHR) ≥ 75 b.p.m., left ventricular ejection fraction (LVEF) ≤ 25%, New York Heart Association (NYHA) Class III/IV, and their combination. Methods and results: The SHIFT trial enrolled 6505 patients (LVEF ≤ 35% and RHR ≥ 70 b.p.m.), randomized to ivabradine or placebo on the background of guideline‐defined standard care. Compared with placebo, ivabradine was associated with a similar relative risk reduction of the primary endpoint (cardiovascular death or HF hospitalization) in patients with SBP < 110 and ≥110 mmHg [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.74–1.08 vs. HR 0.80, 95% CI 0.72–0.89, P interaction = 0.34], LVEF ≤ 25% and >25% (HR 0.85, 95% CI 0.72–1.01 vs. HR 0.80, 95% CI 0.71–0.90, P interaction = 0.53), and NYHA III–IV and II (HR 0.83, 95% CI 0.74–0.94 vs. HR 0.81, 95% CI 0.69–0.94, P interaction = 0.79). The effect was more pronounced in patients with RHR ≥ 75 compared with <75 (HR 0.76, 95% CI 0.68–0.85 vs. HR 0.97, 95% CI 0.81–0.1.16, P interaction = 0.02). When combining these profiling parameters, treatment with ivabradine was also associated with risk reductions comparable with patients with low‐risk profiles for the primary endpoint (relative risk reduction 29%), cardiovascular death (11%), HF death (49%), and HF hospitalization (38%; all P values for interaction: 0.40). No safety concerns were observed between study groups. Conclusions: Our analysis shows that RHR reduction with ivabradine is effective and improves clinical outcomes in HF patients across various risk indicators such as low SBP, high RHR, low LVEF, and high NYHA class to a similar extent and without safety concern. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Le point sur le dictionnaire de l’ANM du 1er janvier 2015 au 26 septembre 2016: (En séance le du 24 mai 2016 — actualisé le 26 septembre 2016)

Author

Buffet, Catherine, Marcelli, Aline, Bedouelle, Jean, Delmas, Vincent, Frottier, Jacques, Giudicelli, Claude-Pierre, Germain, Michel, Hureau, Jacques, Morvan, Gérard, Rodhain, François, Rouëssé, Jacques, Maquart, François-Xavier, Jean-LouisWemeau, Michaux, Jean-Louis, Ardaillou, Raymond, Arné, Jean-Louis, Barthélémy, Catherine, Bounhoure, Jean-Paul, Cordier, Jean-François, Dréno, Brigitte, Falissard, Bruno, Leger, Jean-Marc, Géraut, Christian, Komajda, Michel, Koskas, Fabien, Michel, Jean-Pierre, Milliez, Jacques, Olier, Jean-Pierre, Touitou, Yvan, Touze, Jean-Etienne, and Trèves, Richard

Published
2015
Full Text
View/download PDF

43. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction)

Author

Carson, Peter E., Anand, Inder S., Win, Sithu, Rector, Thomas, Haass, Markus, Lopez-Sendon, Jose, Miller, Alan, Teerlink, John R., White, Michel, McKelvie, Robert S., Komajda, Michel, Zile, Michael R., McMurray, John J., and Massie, Barry

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results